The present disclosure relates to percutaneous circulatory support systems. More specifically, the disclosure relates to percutaneous circulatory support devices that facilitate reduced hemolysis and/or related complications.
Percutaneous circulatory support devices such as devices can provide transient support for up to approximately several weeks in patients with compromised heart function or cardiac output. Operation of such devices, however, may cause some amount of hemolysis (that is, the rupture or destroying of blood cells) or other complications. Hemolysis can in turn cause thrombi formation or other complications. Accordingly, there is a need for improved devices that facilitate reduced hemolysis and/or related complications.
In an Example 1, a percutaneous circulatory support device comprises a housing comprising a proximal end portion; a motor carried by the housing; a driving magnet operatively coupled to the motor; a driven magnet operatively coupled to the driving magnet; the driven magnet comprising a frustoconical shape; and an impeller disposed within the housing, the impeller being operatively coupled to the driven magnet.
In an Example 2, the percutaneous circulatory support device of Example 1, further comprising an outlet, and wherein the driven magnet is disposed apart from the outlet to define an inverse frustoconical chamber in the housing.
In an Example 3, the percutaneous circulatory support device of either of Examples 1 or 2, further comprising an impeller shaft being fixed relative to the impeller and the driven magnet.
In an Example 4, the percutaneous circulatory support device of any of Examples 1 to 3, further comprising a bearing disposed between the driving magnet and the driven magnet.
In an Example 5, the percutaneous circulatory support device of any of Examples 1 to 4, wherein the driven magnet tapers radially inwardly proceeding in a proximal direction.
In an Example 6, the percutaneous circulatory support device of any of Examples 1 to 4, wherein the driven magnet tapers radially inwardly proceeding in a distal direction.
In an Example 7, the percutaneous circulatory support device of any of Examples 1 to 6, wherein the housing comprises a plurality of outlet apertures each extending to a proximal end of the driven magnet.
In an Example 8, the percutaneous circulatory support device of any of Examples 1 to 7, wherein a proximal portion of the impeller comprises a flattened shape.
In an Example 9, a percutaneous circulatory support device comprises a housing comprising a proximal end portion, an inlet, and an outlet; a motor carried by the housing; a driving magnet operatively coupled to the motor; a driven magnet operatively coupled to the driving magnet; the driven magnet comprising a frustoconical shape and being disposed apart from the outlet to define an inverse frustoconical chamber in the proximal end portion of the housing; and an impeller disposed within the housing, the impeller being operatively coupled to the driven magnet.
In an Example 10, the percutaneous circulatory support device of Example 9, further comprising an impeller shaft being fixed relative to the impeller and the driven magnet.
In an Example 11, the percutaneous circulatory support device of either of Examples 9 or 10, wherein the driven magnet tapers radially inwardly proceeding in a proximal direction.
In an Example 12, the percutaneous circulatory support device of either of Examples 9 or 10, wherein the driven magnet tapers radially inwardly proceeding in a distal direction.
In an Example 13, the percutaneous circulatory support device of any of Examples 9 to 12, wherein the outlet comprises a plurality of outlet apertures each extending to a proximal end of the driven magnet.
In an Example 14, the percutaneous circulatory support device of any of Examples 9 to 13, wherein a proximal portion of the impeller comprises a flattened shape.
In an Example 15, the percutaneous circulatory support device of any of Examples 9 to 14, wherein the housing comprises a motor housing carrying the motor and an impeller housing carrying the impeller.
In an Example 16, a percutaneous circulatory support device comprises an impeller housing comprising a proximal end portion; a motor housing coupled to the impeller housing; a motor carried by the motor housing; a driving magnet operatively coupled to the motor; a driven magnet operatively coupled to the driving magnet; the driven magnet comprising a frustoconical shape; and an impeller disposed within the impeller housing, the impeller being operatively coupled to the driven magnet; wherein the motor rotates the impeller, via the driving magnet and the driven magnet, relative to the impeller housing to cause blood to flow through the percutaneous circulatory support device and blood is inhibited from pooling in the proximal end portion of the impeller housing.
In an Example 17, the percutaneous circulatory support device of Example 16, further comprising an outlet, and wherein the driven magnet is disposed apart from the outlet to define an inverse frustoconical chamber in the impeller housing.
In an Example 18, the percutaneous circulatory support device of Example 16, further comprising an impeller shaft being fixed relative to the impeller and the driven magnet.
In an Example 19, the percutaneous circulatory support device of Example 16, wherein the driving magnet is disposed within the motor housing and the driven magnet is disposed within the impeller housing.
In an Example 20, the percutaneous circulatory support device of Example 16, further comprising a bearing disposed between the driving magnet and the driven magnet.
In an Example 21, the percutaneous circulatory support device of Example 16, wherein the driven magnet tapers radially inwardly proceeding in a proximal direction.
In an Example 22, the percutaneous circulatory support device of Example 16, wherein the driven magnet tapers radially inwardly proceeding in a distal direction.
In an Example 23, the percutaneous circulatory support device of Example 16, wherein the impeller housing comprises a plurality of outlet apertures each extending to a proximal end of the driven magnet.
In an Example 24, the percutaneous circulatory support device of Example 16, wherein a proximal portion of the impeller comprises a flattened shape.
In an Example 25, a percutaneous circulatory support device comprises an impeller housing comprising a proximal end portion, an inlet, and an outlet; a motor housing coupled to the impeller housing; a motor carried by the motor housing; a driving magnet operatively coupled to the motor; a driven magnet operatively coupled to the driving magnet; the driven magnet comprising a frustoconical shape and being disposed apart from the outlet to define an inverse frustoconical chamber in the proximal end portion of the impeller housing; and an impeller disposed within the impeller housing, the impeller being operatively coupled to the driven magnet; wherein the motor rotates the impeller, via the driving magnet and the driven magnet, relative to the impeller housing to cause blood to flow through the percutaneous circulatory support device and blood is inhibited from pooling in the proximal end portion of the impeller housing.
In an Example 26, the percutaneous circulatory support device of Example 25, further comprising an impeller shaft being fixed relative to the impeller and the driven magnet.
In an Example 27, the percutaneous circulatory support device of Example 25, wherein the driven magnet tapers radially inwardly proceeding in a proximal direction.
In an Example 28, the percutaneous circulatory support device of Example 25, wherein the driven magnet tapers radially inwardly proceeding in a distal direction.
In an Example 29, the percutaneous circulatory support device of Example 25, wherein the outlet comprises a plurality of outlet apertures each extending to a proximal end of the driven magnet.
In an Example 30, the percutaneous circulatory support device of Example 25, wherein a proximal portion of the impeller comprises a flattened shape.
In an Example 31, a method for using a percutaneous circulatory support device comprises positioning the percutaneous circulatory support device at a target location within a patient; rotating an impeller of the percutaneous circulatory support device, via a motor, a driving magnet, and a driven magnet comprising a frustoconical shape, to cause blood to flow through the percutaneous circulatory support device, wherein blood is inhibited from pooling in a proximal end portion of an impeller housing of the percutaneous circulatory support device.
In an Example 32, the method of Example 31, wherein rotating the impeller and rotating the driven magnet comprise rotating the impeller and the driven magnet together relative to the impeller housing.
In an Example 33, the method of Example 31, wherein the driven magnet tapers radially inwardly proceeding in a proximal direction.
In an Example 34, the method of Example 31, wherein the driven magnet tapers radially inwardly proceeding in a proximal direction.
In an Example 35, the method of Example 31, wherein the percutaneous circulatory support device further comprises an outlet, and the outlet comprises a plurality of outlet apertures each extending to a proximal end of the driven magnet.
While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
With continued reference to
The impeller housing 102 carries an impeller assembly 106 therein. The impeller assembly 106 includes an impeller shaft 108 (
With continued reference to
In some embodiments, a controller (not shown) may be operably coupled to the motor 118 and configured to control the motor 118. In some embodiments, the controller may be disposed within the motor housing 104. In other embodiments, the controller may be disposed outside of the motor housing 104 (for example, in a catheter handle, an independent housing, etc.). In some embodiments, the controller may include multiple components, one or more of which may be disposed within the motor housing 104. According to embodiments, the controller may be, may include, or may be included in one or more Field Programmable Gate Arrays (FPGAs), one or more Programmable Logic Devices (PLDs), one or more Complex PLDs (CPLDs), one or more custom Application Specific Integrated Circuits (ASICs), one or more dedicated processors (e.g., microprocessors), one or more Central Processing Units (CPUs), software, hardware, firmware, or any combination of these and/or other components. Although the controller is referred to herein in the singular, the controller may be implemented in multiple instances, distributed across multiple computing devices, instantiated within multiple virtual machines, and/or the like. In other embodiments, the motor 118 may be controlled in other manners.
With further reference to
The device 100 may also include one or more additional features that facilitate reduced device-induced hemolysis compared to conventional devices. For example, the apertures of the outlet 116 may be relatively long compared to those of conventional devices. More specifically, the apertures of the outlet 116 may each extend to a proximal end 132 (
Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.
This application claims priority to Provisional Application No. 63/282,207, filed Nov. 23, 2021, which is herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
5021048 | Buckholtz | Jun 1991 | A |
5145333 | Smith | Sep 1992 | A |
5211546 | Isaacson et al. | May 1993 | A |
5527159 | Bozeman, Jr. et al. | Jun 1996 | A |
5611679 | Ghosh et al. | Mar 1997 | A |
5692882 | Bozeman, Jr. et al. | Dec 1997 | A |
5928131 | Prem | Jul 1999 | A |
5947703 | Nojiri et al. | Sep 1999 | A |
5947892 | Benkowski et al. | Sep 1999 | A |
5964694 | Siess et al. | Oct 1999 | A |
6056520 | Nguyen et al. | May 2000 | A |
6135729 | Aber | Oct 2000 | A |
6139487 | Siess | Oct 2000 | A |
6176822 | Nix et al. | Jan 2001 | B1 |
6176848 | Rau et al. | Jan 2001 | B1 |
6201329 | Chen | Mar 2001 | B1 |
6227820 | Jarvik | May 2001 | B1 |
6264635 | Wampler et al. | Jul 2001 | B1 |
6447266 | Antaki et al. | Sep 2002 | B2 |
7841976 | McBride et al. | Nov 2010 | B2 |
7927068 | McBride et al. | Apr 2011 | B2 |
7972122 | Larose et al. | Jul 2011 | B2 |
8007254 | Larose et al. | Aug 2011 | B2 |
8043074 | Tada | Oct 2011 | B2 |
8376707 | McBride et al. | Feb 2013 | B2 |
8512012 | Akdis et al. | Aug 2013 | B2 |
8591393 | Walters et al. | Nov 2013 | B2 |
8597170 | Walters et al. | Dec 2013 | B2 |
8684904 | Campbell et al. | Apr 2014 | B2 |
8721517 | Zeng et al. | May 2014 | B2 |
8770945 | Ozaki et al. | Jul 2014 | B2 |
8827661 | Mori | Sep 2014 | B2 |
8992163 | McBride et al. | Mar 2015 | B2 |
9067005 | Ozaki et al. | Jun 2015 | B2 |
9072825 | Pfeffer et al. | Jul 2015 | B2 |
9091271 | Bourque | Jul 2015 | B2 |
9138518 | Yuen et al. | Sep 2015 | B2 |
9162017 | Evans et al. | Oct 2015 | B2 |
9199020 | Siess | Dec 2015 | B2 |
9308302 | Zeng | Apr 2016 | B2 |
9308304 | Peters et al. | Apr 2016 | B2 |
9314557 | Ricci et al. | Apr 2016 | B2 |
9327067 | Zeng et al. | May 2016 | B2 |
9364592 | McBride et al. | Jun 2016 | B2 |
9364593 | McBride et al. | Jun 2016 | B2 |
9364594 | Nsser et al. | Jun 2016 | B2 |
9381288 | Schenck et al. | Jul 2016 | B2 |
9398743 | Fox et al. | Jul 2016 | B1 |
9421311 | Tanner et al. | Aug 2016 | B2 |
9446179 | Keenan et al. | Sep 2016 | B2 |
9616157 | Akdis | Apr 2017 | B2 |
9717833 | McBride et al. | Aug 2017 | B2 |
9737652 | LaRose et al. | Aug 2017 | B2 |
9770543 | Tanner et al. | Sep 2017 | B2 |
9872947 | Keenan et al. | Jan 2018 | B2 |
9895476 | Larose et al. | Feb 2018 | B2 |
9907890 | Muller | Mar 2018 | B2 |
9956332 | Larose et al. | May 2018 | B2 |
9962475 | Yuen et al. | May 2018 | B2 |
9964115 | Scheckel | May 2018 | B2 |
10029037 | Muller et al. | Jul 2018 | B2 |
10039872 | Zeng et al. | Aug 2018 | B2 |
10071192 | Zeng | Sep 2018 | B2 |
10086121 | Fitzgerald et al. | Oct 2018 | B2 |
10105475 | Muller | Oct 2018 | B2 |
10117980 | Keenan et al. | Nov 2018 | B2 |
10149932 | McBride et al. | Dec 2018 | B2 |
10215187 | McBride et al. | Feb 2019 | B2 |
10232099 | Peters et al. | Mar 2019 | B2 |
10251985 | Larose et al. | Apr 2019 | B2 |
10251986 | Larose et al. | Apr 2019 | B2 |
10478539 | Pfeffer et al. | Nov 2019 | B2 |
10478540 | Scheckel et al. | Nov 2019 | B2 |
10525178 | Zeng | Jan 2020 | B2 |
10576192 | Muller et al. | Mar 2020 | B2 |
10576193 | Tanner et al. | Mar 2020 | B2 |
10704553 | Janeczek et al. | Jul 2020 | B2 |
10709829 | Muller | Jul 2020 | B2 |
10709830 | Tanner et al. | Jul 2020 | B2 |
10765789 | Zeng et al. | Sep 2020 | B2 |
10780208 | Siess et al. | Sep 2020 | B2 |
10786610 | Zeng | Sep 2020 | B2 |
10799624 | Pfeffer et al. | Oct 2020 | B2 |
10842921 | Siess et al. | Nov 2020 | B2 |
10864308 | Muller et al. | Dec 2020 | B2 |
10864309 | McBride et al. | Dec 2020 | B2 |
10874783 | Pfeffer et al. | Dec 2020 | B2 |
10894115 | Pfeffer et al. | Jan 2021 | B2 |
10918774 | Stanfield et al. | Feb 2021 | B2 |
10960116 | Yuen et al. | Mar 2021 | B2 |
10973967 | Nyikos et al. | Apr 2021 | B2 |
10980927 | Pfeffer et al. | Apr 2021 | B2 |
11058865 | Fitzgerald et al. | Jul 2021 | B2 |
11097092 | Siess et al. | Aug 2021 | B2 |
11107626 | Siess et al. | Aug 2021 | B2 |
11123539 | Pfeffer et al. | Sep 2021 | B2 |
11129978 | Pfeffer et al. | Sep 2021 | B2 |
11167124 | Pfeffer et al. | Nov 2021 | B2 |
11219755 | Siess et al. | Jan 2022 | B2 |
11229786 | Zeng et al. | Jan 2022 | B2 |
11235138 | Gross-Hardt et al. | Feb 2022 | B2 |
11253693 | Pfeffer et al. | Feb 2022 | B2 |
11260213 | Zeng et al. | Mar 2022 | B2 |
11273301 | Pfeffer et al. | Mar 2022 | B2 |
11311712 | Zeng et al. | Apr 2022 | B2 |
11338124 | Pfeffer et al. | May 2022 | B2 |
11357967 | Zeng et al. | Jun 2022 | B2 |
11400276 | Chopra et al. | Aug 2022 | B2 |
11471664 | Xu et al. | Oct 2022 | B2 |
11497896 | Tanner et al. | Nov 2022 | B2 |
11517736 | Earles et al. | Dec 2022 | B2 |
11569015 | Mourran et al. | Jan 2023 | B2 |
11583659 | Pfeffer et al. | Feb 2023 | B2 |
11628294 | Chopra et al. | Apr 2023 | B2 |
11648388 | Siess | May 2023 | B2 |
11672968 | Antaki | Jun 2023 | B2 |
11708833 | McBride et al. | Jul 2023 | B2 |
11754075 | Schuelke et al. | Sep 2023 | B2 |
11786700 | Pfeffer et al. | Oct 2023 | B2 |
11813443 | Hanson et al. | Nov 2023 | B2 |
20030233021 | Nose et al. | Dec 2003 | A1 |
20060222533 | Reeves et al. | Oct 2006 | A1 |
20080114339 | McBride et al. | May 2008 | A1 |
20090060743 | McBride et al. | Mar 2009 | A1 |
20090093764 | Pfeffer et al. | Apr 2009 | A1 |
20090171137 | Farnan et al. | Jul 2009 | A1 |
20110237863 | Ricci et al. | Sep 2011 | A1 |
20110238172 | Akidis | Sep 2011 | A1 |
20130338559 | Franano et al. | Dec 2013 | A1 |
20140005467 | Farnan et al. | Jan 2014 | A1 |
20140010686 | Tanner et al. | Jan 2014 | A1 |
20140336446 | Rodefield | Nov 2014 | A1 |
20160271308 | LaRose et al. | Sep 2016 | A1 |
20170043074 | Siess | Feb 2017 | A1 |
20170296725 | Peters et al. | Oct 2017 | A1 |
20180303990 | Siess et al. | Oct 2018 | A1 |
20180311423 | Zeng et al. | Nov 2018 | A1 |
20190275224 | Hanson et al. | Sep 2019 | A1 |
20200306434 | Vancamp et al. | Oct 2020 | A1 |
20210015982 | Kerkhoffs et al. | Jan 2021 | A1 |
20210023282 | Siess et al. | Jan 2021 | A1 |
20210038785 | Siess et al. | Feb 2021 | A1 |
20210069393 | Schauer et al. | Mar 2021 | A1 |
20210106810 | Pfeffer et al. | Apr 2021 | A1 |
20220134082 | Pfeffer et al. | May 2022 | A1 |
20220384070 | Mourran | Dec 2022 | A1 |
20230040593 | Liu et al. | Feb 2023 | A1 |
20240075275 | Earles | Mar 2024 | A1 |
Number | Date | Country |
---|---|---|
3338002 | May 1985 | DE |
0847767 | Feb 2005 | EP |
2301598 | Jul 2017 | EP |
3352808 | Sep 2023 | EP |
9500185 | Jan 1995 | WO |
0117581 | Mar 2001 | WO |
2018197306 | Nov 2018 | WO |
2019135767 | Jul 2019 | WO |
2021113389 | Jun 2021 | WO |
Entry |
---|
US 9,067,007 B2, 06/2015, Tanner et al. (withdrawn) |
International Search Report and Written Opinion for International Application No. PCT/US2022/050053 dated Mar. 6, 2023. (14 pages). |
International Search Report and Written Opinion for International Application No. PCT/US2022/050694 dated Apr. 5, 2023. (14 pages). |
Number | Date | Country | |
---|---|---|---|
20230158286 A1 | May 2023 | US |
Number | Date | Country | |
---|---|---|---|
63282207 | Nov 2021 | US |